Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria

SpringerPlus

Table 2 Cost-effectiveness of ODX in the Austrian setting

Strategy	Base-case analysis				∆Total costs × 1000€	ICER (€/QALY)
Strategy	LYs	QALYs	∆QALYs	Total costs ×1000€	∆Total costs × 1000€	ICER (€/QALY)
1-NNN	14.33	11.08	–	13.18	–	NA^a
3-NYN	14.46	11.18	–	13.36	–	D^b
2-NNY	14.60	11.29	–	13.58	–	D
4-NYY	14.73	11.40	0.32	13.71	0.53	1628.35
5-YNN	14.46	11.17	–	15.48	–	D
7-YYN	14.64	11.31	–	15.61	–	D
6-YNY	14.76	11.41	–	15.81	–	D
8-YYY	14.92	11.54	0.14	15.93	2.22	15,727.78